The endocannabinoid system and bone

Czech version

Authors: Mikuláš Pura ^1,2,3; Peter Vaňuga ¹
Authors‘ workplace: Národný endokrinologický a diabetologický ústav, Ľubochňa, Slovenská republika ¹; Endokrinologická ambulancia, Ružomberok, Slovenská republika ²; Endokrinologická ambulancia, Poliklinika Novamed, Banská Bystrica, Slovenská republika ³
Published in: Vnitř Lék 2016; 62(Suppl 3): 99-102
Category: Reviews

Pribúdajú dôkazy o tom, že kostný endokanabinoidný systém zohráva dôležitú úlohu v regulácii kostnej hmoty za fyziologických aj patologických podmienok. Oba hlavné endokanabinoidné ligandy (anandamid aj 2-arachidonoylglycerol), receptory endokanabinoidného systému – CB1-receptor (CB1R) a CB2-receptor (CB2R) a kľúčové enzýmy ich syntézy a degradácie sa nachádzajú, resp. sú exprimované v osteoblastoch aj osteoklastoch.

Overview

Recent studies suggest an important role for the skeletal endocannabinoid system in the regulation of bone mass in both physiological and pathological conditions. Both major endocannabinoids (anandamid and 2-arachidonoylglycerol), endocannabinoid receptors – CB₁-receptor (CB₁R) a CB₂-receptor (CB₂R) and the endocannabinoid metabolizing enzymes are present or expressed in osteoblasts and osteoclasts. Previous studies identified multiple risk and protective variants of CNR2 gene dealing with the relationship to bone density and/or osteoporosis. Selective CB₁R/ CB₂R-inverse agonists/antagonists and CB₂R-inverse agonists/antagonists are candidates for prevention of bone mass loss and combined antiresorptive and anabolic therapy for osteoporosis.

Key words:
cannabinoid receptors – endocannabinoids – marijuana – osteoporosis

Sources

1. Bab I, Zimmer A, Melamed E. Cannabinoids and skeleton: from marijuana to reversal of bone loss. Ann Med 2009; 41(8): 560–567. Dostupné z DOI: <http://dx.doi.org/10.1080/07853890903121025>.

2. Lambert DM, Fowler CJ. The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J Med Chem 2005; 48(16): 5059–5087.

3. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006; 147(Suppl 1): S163-S171.

4. Kogan NM, Mechoulam R. Cannabinoids in health and disease. Dialogues Clin Neurosci 2007; 9(4): 413–430.

5. Marx J. Drug development. Drugs inspired by a drug. Science 2006; 311(5759): 322–325.

6. Fattore L (ed). Canabinoids in neurologic and mental disease. Elsevier: San Diego 2015. ISBN 978–0124170414

7. Köhler FE. Medizinal-Pflanzen in naturgetreuen Abbildungen mit kurz erläuterndem Texte. Gera-Untermhaus: 1887. Dostupné z WWW: Dostupné z DOI: http://www.botanicus.org/item/31753002839139.

8. Raphael B, Gabet Y. The skeletal endocannabinoid system: clinical and experimental insights. J Basic Clin Physiol Pharmacol 2016; 27(3): 237–245. Dostupné z DOI: <http://dx.doi.org/10.1515/jbcpp-2015–0073>.

9. Ledent C, Valverde O, Cossu G et al. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999; 283(5400): 401–404.

10. Tam J, Ofek O, Fride E et al. Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol 2006; 70(3): 786–792.

11. Idris AI, van’t Hof RJ, Greig IR et al. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat Med 2005; 11(7): 774–779.

12. Bab I, Ofek O, Tam J et al. Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 2008; 20(Suppl 1): S69-S74. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2826.2008.01675.x>.

13. Ofek O, Karsak M, Leclerc N et al. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci 2006; 103(3): 696–701.

14. Brown JP, Delmas PD, Malaval L et al. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984; 1(8386): 1091–1093.

15. Sophocleous A, Idris AI, Ralston SH. Genetic background modifies the effects of type 2 cannabinoid receptor deficiency on bone mass and bone turnover. Calcif Tissue Int 2014; 94(3): 259–268. Dostupné z DOI: <http://dx.doi.org/10.1007/s00223–013–9793–8>.

16. Whyte LS, Rynerg E, Sims NA et al. The putative cannabinoid receptor GPR55 affects osteclast function in vitro and bone mass in vivo. Proc Natl Acad Sci 2009; 106(38): 16511–16516. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.0902743106>.

17. Ryberg E, Larsson N, Sjogren S et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 2007; 152(7): 1092–1101.

18. Begg M, Pacher P, Batkai S et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106(2): 133–145.

19. Idris AI. Cannabinoid receptors as target for treatment of osteoporosis: a tale of two therapies. Curr Neuropharmacol 2010; 8(3): 243–253. Dostupné z DOI: <http://dx.doi.org/10.2174/157015910792246173>.

20. Idris AI, Sophocleous A, Landao-Bassonga E et al. Cannabinoid receptor type 1 protects against age-related osteoporosis by regulating osteoblast and adipocyte differentiation in marrow stromal cells. Cell Metab 2009; 10(2): 139–147. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2009.07.006>.

21. Idris AI, Sophocleous A, Landao-Bassonga E et al. Regulation of bone mass, osteoclast function, and ovariectomy-induced bone loss by the type 2 cannabinoid receptor. Endocrinology 2008; 149(11): 5619–5626. Dostupné z DOI: <http://dx.doi.org/10.1210/en.2008–0150>.

22. Devoto M, Shimoya K, Caminis J et al. First-stage autosomal genome screen in extended pedigrees suggests genes predisposing to low bone mineral density on chromosomes 1p, 2p and 4q. Eur J Hum Genet 1998; 6(2): 151–157.

23. Devoto M, Specchia C, Li HH et al. Variance component linkage analysis indicates a QTL for femoral neck bone mineral density on chromosome 1p36. Hum Mol Genet 2001; 10(21): 2447–2452.

24. Devoto M, Spotila LD, Stabley DL et al. Univariate and bivariate variance component linkage analysis of a whole-genome scan for loci contributing to bone mineral density. Eur J Hum Genet 2005; 13(6): 781–788.

25. Valdéz-Flores M, Casas-Avila L, Ponce de León-Suárez V. Genetic diseases related wih osteoporosis. In: Valdéz-Flores M (ed). Topics in osteoporosis. In Tech. Dostupné z WWW: http://www.intechopen.com/books/howtoreference/topics-in-osteoporosis/genetic-diseases-related-with-osteoporosis.

26. Karsak M, Cohen-Solal M, Freudenberg J et al. Cannabinoid receptor type 2 gene is associated with human osteoporosis. Hum Mol Genet 2005; 14(22): 3389–3396.

27. Yamada Y, Ando F, Shimokata H. Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. Int J Mol Med 2007; 19(5): 791–801.

28. Zhang C, Ma J, Chen G et al. Evaluation of common variants in CNR2 gene for bone mineral density and osteoporosis susceptibility in postmenopausal women of Han Chinese. Osteoporosis Int 2015; 26(12): 2803–2810. Dostupné z DOI: <http://dx.doi.org/10.1007/s00198–015–3195-x>.

29. Woo JH, Kim H, Kim JH et al. Cannabinoid receptor genepolymorphisms and bone mineral density in Korean postmeonpausal women. Menopause 2015; 22(5): 512–519. Dostupné z DOI: <http://dx.doi.org/10.1097/GME.0000000000000339>.

30. Smoum R, Baraghithy S, Chourasia M et al. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: an inverse relationship between binding affinity and biological potency. Proc Natl Acad Sci USA 2015; 112(28): 8774–8779. Dostupné z DOI: <http://dx.doi.org/10.1073/pnas.1503395112>.

31. Raphael B, Gabet Y. The skeletal endocannabinoid system: clinical and experimental insights. J Basic Clin Physiol Pharmacol 2016; 27(3): 237–245. Dostupné z DOI: <http://dx.doi.org/10.1515/jbcpp-2015–0073>.

32. Nutt D, King LA, Saulsbury W et al. Development of a rational scale to assess the harm of drugs of potential misuse. Lancet 2007; 369(9566): 1047–1053.

33. Nutt DJ, King LA, Phillips LD et al. Independent Scientific Committee on Drugs. Drug harms in the UK: a multicriteria decision analysis. Lancet 2010; 376 (9752): 1558–1565. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(10)61462–6>.

34. Hanuš LO, Kotrba Š. Nad léčivými jointy s Lumírem Hanušem. Britské listy [18–09–2008]. Dostupné z WWW: http://blisty.cz/art/42801.html.

35. Holland J (ed). Tráva. Kompletní průvodce světem marihuany v medicíně, vědě, kultuře a politice. Pragma: Praha 2014. ISBN 978–80–7349–408–7

36. Martínez-Pinilla E, Rabal O, Reyes-Resina I et al. Two affinity sites of the cannabinoid subtype 2 receptor identified by a novel homogeneous binding assay. J Pharmacol Exp Ther 2016; 358(3): 580–587. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.116.234948>.